HRP20200034T1 - Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka - Google Patents
Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka Download PDFInfo
- Publication number
- HRP20200034T1 HRP20200034T1 HRP20200034TT HRP20200034T HRP20200034T1 HR P20200034 T1 HRP20200034 T1 HR P20200034T1 HR P20200034T T HRP20200034T T HR P20200034TT HR P20200034 T HRP20200034 T HR P20200034T HR P20200034 T1 HRP20200034 T1 HR P20200034T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- antibody
- acid sequence
- antigen
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 201000011510 cancer Diseases 0.000 title claims 8
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title claims 4
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title claims 4
- 206010006895 Cachexia Diseases 0.000 title claims 3
- 230000004069 differentiation Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102000046181 human GDF15 Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Claims (16)
1. Monoklonsko protutijelo koje se može vezati na ljudski GDF-15, ili njegov dio koji se veže na antigen, naznačeno time što je vezanje vezanje na konformacijski ili diskontinuirani epitop na ljudskom GDF-15 kojeg sadrže aminokiselinski sljedovi SEQ ID No: 25 i SEQ ID No: 26, gdje konstantna domena teškog lanca ima aminokiselinski slijed SEQ ID No: 29, ili aminokiselinski slijed koji mu je u najmanju ruku istovjetan 85 %, te što konstantna domena lakog lanca ima aminokiselinski slijed SEQ ID No: 32, ili aminokiselinski slijed koji mu je u najmanju ruku 85 % istovjetan.
2. Monoklonsko protutijelo koje se može vezati na ljudski GDF-15, ili njegov dio koji se veže na antigen, gdje varijabilna domena teškog lanca sadrži područje CDR3 koje ima aminokiselinski slijed SEQ ID NO: 5, te gdje varijabilna domena lakog lanca sadrži područje CDR3 koje ima aminokiselinski slijed SEQ ID NO: 7,
naznačeno time što konstantna domena teškog lanca ima aminokiselinski slijed SEQ ID No: 29, ili aminokiselinski slijed koji mu je u najmanju ruku istovjetan 85 %, što konstantna domena lakog lanca ima aminokiselinski slijed SEQ ID No: 32, ili aminokiselinski slijed koji mu je u najmanju ruku 85 % istovjetan, što varijabilna domena teškog lanca ima aminokiselinski slijed SEQ ID No: 28, te što varijabilna domena lakog lanca ima aminokiselinski slijed SEQ ID No: 31.
3. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačeno time što je protutijelo humanizirano protutijelo.
4. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjen upotrebi u lijeku.
5. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi u postupku liječenja kaheksije uzrokovane rakom kod sisavca.
6. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi u postupku liječenja raka kod sisavca.
7. Komplet, naznačen time što sadrži protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1-3.
8. Eksprimirajući vektor, naznačen time što sadrži nukleotidni slijed koji kodira protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1-3.
9. Stanična linija, naznačena time što može proizvoditi protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
10. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 5 do 6, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 6, naznačeno time što je postupak postupak istodobno liječenja raka i liječenja kaheksije uzrokovane rakom kod istog sisavca.
11. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10, naznačeno time što stanice raka iz sisavca endogeno eksprimiraju GDF-15 i/ili stanice raka iz sisavca stimuliraju endogeno eksprimiranje GDF-15 u nekanceroznim stanicama iz sisavca.
12. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10 do 11, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10 do 11, naznačeno time što stanice raka iz sisavca endogeno eksprimiraju GDF-15.
13. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10 do 12, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 6 ili 10 do 12, naznačeno time što je sisavac ljudski pacijent.
14. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 10-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 10-13, ili protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1 ili 3, naznačeno time što varijabilna domena teškog lanca sadrži područje CDR3 koje ima aminokiselinski slijed SEQ ID NO: 5 ili aminokiselinski slijed koji mu je u najmanju ruku istovjetan 90 %, te što varijabilna domena lakog lanca sadrži područje CDR3 koje ima aminokiselinski slijed SEQ ID NO: 7 ili aminokiselinski slijed koji mu je u najmanju ruku istovjetan 85 %.
15. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 10-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 10-13, ili protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 2 i 3, naznačeno time što je vezanje vezanje na konformacijski ili diskontinuirani epitop na ljudskom GDF-15 kojeg sadrže aminokiselinski sljedovi SEQ ID No: 25 i SEQ ID No: 26.
16. Protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 10-15, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 10-15, ili protutijelo, ili njegov dio koji se veže na antigen, u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što varijabilna domena teškog lanca sadrži područje CDR1 koje ima aminokiselinski slijed SEQ ID NO: 3 i područje CDR2 koje ima aminokiselinski slijed SEQ ID NO: 4, te što varijabilna domena lakog lanca sadrži područje CDR1 koje ima aminokiselinski slijed SEQ ID NO: 6 i područje CDR2 koje ima aminokiselinski slijed Ser-Ala-Ser.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405477.9A GB2524553C (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| GB1405475.3A GB2524552B (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| PCT/EP2015/056654 WO2015144855A1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| EP15712629.3A EP3122775B1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200034T1 true HRP20200034T1 (hr) | 2020-03-20 |
Family
ID=52745885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231514TT HRP20231514T1 (hr) | 2014-03-26 | 2015-03-26 | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka |
| HRP20200034TT HRP20200034T1 (hr) | 2014-03-26 | 2020-01-09 | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231514TT HRP20231514T1 (hr) | 2014-03-26 | 2015-03-26 | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US20170204174A1 (hr) |
| EP (3) | EP3653644B1 (hr) |
| JP (3) | JP6865585B2 (hr) |
| KR (1) | KR102520978B1 (hr) |
| CN (1) | CN106536553B (hr) |
| AU (2) | AU2015238264B2 (hr) |
| BR (2) | BR112016022013A2 (hr) |
| CA (1) | CA2943694A1 (hr) |
| CY (1) | CY1122456T1 (hr) |
| DK (2) | DK3653644T3 (hr) |
| ES (2) | ES2965626T3 (hr) |
| FI (1) | FI3653644T3 (hr) |
| HR (2) | HRP20231514T1 (hr) |
| HU (2) | HUE064573T2 (hr) |
| IL (2) | IL248038B (hr) |
| LT (2) | LT3122775T (hr) |
| NZ (1) | NZ724649A (hr) |
| PL (2) | PL3653644T3 (hr) |
| PT (2) | PT3653644T (hr) |
| RS (1) | RS59700B1 (hr) |
| SI (1) | SI3122775T1 (hr) |
| WO (1) | WO2015144855A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015144855A1 (en) | 2014-03-26 | 2015-10-01 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| US20170306008A1 (en) | 2014-09-25 | 2017-10-26 | Aveo Pharmaceuticals, Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| AU2016333538B2 (en) * | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| BR112018006218A2 (pt) * | 2015-10-02 | 2018-10-09 | Univ Wuerzburg J Maximilians | iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15 |
| GB201517528D0 (en) * | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| JP7138567B2 (ja) * | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| US10738115B2 (en) * | 2016-07-06 | 2020-08-11 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
| AU2017342028A1 (en) * | 2016-10-12 | 2019-04-11 | Janssen Biotech, Inc. | Methods for screening for modulators of GDF15-like biological activity |
| JP7134960B2 (ja) * | 2016-12-06 | 2022-09-12 | セントビンセンツ ホスピタル シドニー リミテッド | 肥満及び摂食障害の治療 |
| KR20210049840A (ko) * | 2018-08-20 | 2021-05-06 | 화이자 인코포레이티드 | 항-gdf15 항체, 조성물 및 사용 방법 |
| EP4243928A1 (en) * | 2020-11-10 | 2023-09-20 | CatalYm GmbH | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
| AU2022251923A1 (en) | 2021-03-31 | 2023-11-16 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| IL310535A (en) | 2021-08-10 | 2024-03-01 | Byomass Inc | Anti-GDF15 antibodies, compositions and uses thereof |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023217068A1 (zh) * | 2022-05-09 | 2023-11-16 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| EP1704166B1 (en) * | 2004-01-07 | 2015-04-29 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
| PL2441466T3 (pl) * | 2004-04-13 | 2015-01-30 | St Vincents Hospital Sydney Ltd | Środek hamujący MIC-1 |
| EP2187933A4 (en) | 2007-08-16 | 2010-12-08 | St Vincents Hosp Sydney | AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE ACTIVITY (MIC-1) |
| WO2009046495A1 (en) * | 2007-10-09 | 2009-04-16 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| AU2009296299A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human IL 17 and uses thereof |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| RS57038B1 (sr) * | 2010-11-17 | 2018-05-31 | Chugai Pharmaceutical Co Ltd | Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| DK2900263T3 (da) * | 2012-09-26 | 2019-07-29 | Univ Wuerzburg J Maximilians | Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) |
| AR094271A1 (es) * | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15 |
| WO2015144855A1 (en) | 2014-03-26 | 2015-10-01 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
-
2015
- 2015-03-26 WO PCT/EP2015/056654 patent/WO2015144855A1/en active Application Filing
- 2015-03-26 HR HRP20231514TT patent/HRP20231514T1/hr unknown
- 2015-03-26 FI FIEP19205321.3T patent/FI3653644T3/fi active
- 2015-03-26 DK DK19205321.3T patent/DK3653644T3/da active
- 2015-03-26 BR BR112016022013A patent/BR112016022013A2/pt active Search and Examination
- 2015-03-26 BR BR122023027559-4A patent/BR122023027559A2/pt unknown
- 2015-03-26 JP JP2016559286A patent/JP6865585B2/ja active Active
- 2015-03-26 PT PT192053213T patent/PT3653644T/pt unknown
- 2015-03-26 ES ES19205321T patent/ES2965626T3/es active Active
- 2015-03-26 LT LTEP15712629.3T patent/LT3122775T/lt unknown
- 2015-03-26 HU HUE19205321A patent/HUE064573T2/hu unknown
- 2015-03-26 EP EP19205321.3A patent/EP3653644B1/en active Active
- 2015-03-26 CA CA2943694A patent/CA2943694A1/en active Pending
- 2015-03-26 ES ES15712629T patent/ES2763859T3/es active Active
- 2015-03-26 PT PT157126293T patent/PT3122775T/pt unknown
- 2015-03-26 DK DK15712629.3T patent/DK3122775T3/da active
- 2015-03-26 NZ NZ724649A patent/NZ724649A/en unknown
- 2015-03-26 LT LTEP19205321.3T patent/LT3653644T/lt unknown
- 2015-03-26 EP EP23203704.4A patent/EP4316596A3/en active Pending
- 2015-03-26 US US15/128,604 patent/US20170204174A1/en not_active Abandoned
- 2015-03-26 CN CN201580027932.8A patent/CN106536553B/zh active Active
- 2015-03-26 RS RS20191652A patent/RS59700B1/sr unknown
- 2015-03-26 PL PL19205321.3T patent/PL3653644T3/pl unknown
- 2015-03-26 AU AU2015238264A patent/AU2015238264B2/en active Active
- 2015-03-26 PL PL15712629T patent/PL3122775T3/pl unknown
- 2015-03-26 EP EP15712629.3A patent/EP3122775B1/en active Active
- 2015-03-26 KR KR1020167029710A patent/KR102520978B1/ko active IP Right Grant
- 2015-03-26 HU HUE15712629A patent/HUE047398T2/hu unknown
- 2015-03-26 SI SI201531059T patent/SI3122775T1/sl unknown
-
2016
- 2016-09-26 IL IL248038A patent/IL248038B/en active IP Right Grant
-
2018
- 2018-03-05 US US15/912,358 patent/US10604565B2/en active Active
-
2020
- 2020-01-08 CY CY20201100008T patent/CY1122456T1/el unknown
- 2020-01-09 HR HRP20200034TT patent/HRP20200034T1/hr unknown
- 2020-02-19 US US16/794,406 patent/US11760795B2/en active Active
- 2020-02-19 US US16/794,401 patent/US11634482B2/en active Active
- 2020-07-30 IL IL276405A patent/IL276405B/en unknown
- 2020-10-28 AU AU2020260440A patent/AU2020260440B2/en active Active
-
2021
- 2021-04-06 JP JP2021064572A patent/JP2021119138A/ja active Pending
-
2023
- 2023-04-06 JP JP2023062338A patent/JP2023098966A/ja active Pending
- 2023-08-02 US US18/364,173 patent/US20230382987A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| JP2017508475A5 (hr) | ||
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| PH12019500545A1 (en) | Cd3 binding antibodies | |
| WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| PH12019502459A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| MX2018016404A (es) | Anticuerpos de union a cd3. | |
| PH12017500268A1 (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| EA201600276A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
| RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) | |
| JP2017518260A5 (hr) | ||
| JP2021500916A5 (hr) | ||
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
| EA201692495A8 (ru) | Биспецифические антитела к il4-il13 |